Conclusion
In the light of the current results; combined septal and turbinate injection of BTX-A seems to be a safe and efficient therapeutic choice for controlling allergic rhinitis symptoms, especially nasal hypersecretions with a long-lasting effect. Further studies with extended follow-ups are needed to objectively evaluate the injection effect, and to determine the efficacy duration and the optimal dose of BTX-A in allergic rhinitis.